S851 Health-Related Quality of Life With Ustekinumab vs Adalimumab for Induction and Maintenance Therapy in Biologic-Naïve Patients With Moderate-To-Severe Crohn's Disease: PROMIS-29 in the SEAVUE Study. (October 2021) - Lewis, James D.; Allez, Matthieu; Irving, Peter M.; Hoops, Timothy; Izanec, James L.; Ma, Tony; Ding, Zhijie; Muser, Erik; Gasink, Christopher; Panaccione, Remo; Loftus, Edward V.; Danese, Silvio; et al.